One of the most advanced projects involves a new nanomedicine designed to treat sepsis, a life-threatening condition in which the body’s response to infection becomes dangerously dysregulated. Assistant professor and Presidential Frontier Faculty member Fanfei Meng is developing a nanoparticle-based drug delivery system that combines antibacterial treatment with immune regulation. His team is pursuing patent protection for the technology after preliminary experiments produced what researchers describe as highly encouraging results.

Sepsis can begin when bacteria enter the bloodstream or infect tissues, but the danger extends beyond the microbes themselves. In severe cases, the immune system releases a cascade of inflammatory signals that can damage blood vessels, disrupt circulation and impair the function of vital organs. Antibiotics may eliminate bacteria without fully controlling this inflammatory response, while immune-suppressing drugs can carry their own risks. Meng’s approach is designed to address both sides of the disease process at the same time.

The nanoparticle carries two complementary therapies: an antibiotic intended to destroy the underlying bacteria and an immunomodulator intended to reduce excessive inflammatory signaling. Encapsulation within a nanoscale delivery system may help control how the drugs circulate, reach tissues and interact with one another. According to Meng, the formulation reduced drug toxicity, retained strong antibacterial activity and broadly suppressed inflammatory pathways. In a preclinical model of severe sepsis, the treatment achieved complete survival, a result that will need to be tested through additional studies before its relevance to human patients can be determined.

A separate project is applying artificial intelligence to the search for treatments for Alzheimer’s disease and related dementias. Tiansheng Wang, an assistant professor in the Department of Pharmaceutical Health Outcomes and Policy, is focusing on drug repurposing—the investigation of whether medicines already approved for one condition might also protect cognitive function or slow disease-related decline. Repurposing can potentially shorten the path to clinical testing because existing drugs have already undergone studies of manufacturing, dosing and safety.

Wang’s project will use AI to examine several categories of information that are often analyzed independently. These include medication histories and other real-world health data, genetic information, cognitive assessments and brain imaging. Integrating these sources could allow researchers to identify patterns that emerge before a formal dementia diagnosis appears in a medical record. Earlier indicators may also help distinguish whether a medication is associated with meaningful changes in cognitive performance, brain structure or disease risk.

The project reflects a broader shift in biomedical research toward computational methods capable of finding relationships within large, complex datasets. An AI system could screen many approved medicines and compare their effects across patient groups, genetic profiles and stages of cognitive change. Such findings would not by themselves prove that a drug treats dementia, but they could help prioritize the most promising candidates for laboratory experiments and clinical studies, potentially reducing the time and cost required to identify new therapeutic options.

The third investigation addresses depression among people with sickle cell disease, an inherited blood disorder in which abnormal hemoglobin causes red blood cells to become rigid and prone to blocking blood vessels. These blockages can produce episodes of severe pain, anemia and long-term organ complications. Research assistant professor Onye Ononogbu of Pharmacy Practice and Translational Research is creating a screening tool specifically for this patient population, where conventional depression assessments may be difficult to interpret.

The challenge is that many physical features of sickle cell disease overlap with symptoms commonly used to identify depression. Fatigue, disrupted sleep and changes in appetite may arise from depression, chronic pain, anemia or the cumulative demands of living with a serious illness. A screening instrument designed around the experiences of people with sickle cell disease could help clinicians separate psychological symptoms from disease-related physical effects, identify patients who need further evaluation and support more timely care. Together, the three projects show how nanotechnology, artificial intelligence and disease-specific clinical tools are being brought to bear on conditions that have resisted one-size-fits-all solutions.

Subject of Research: Sepsis treatment, nanomedicine, drug delivery, artificial intelligence for Alzheimer’s disease and related dementias, and depression screening in sickle cell disease.

Article Title: University of Houston Researchers Advance Nanomedicine, AI Drug Repurposing and Sickle Cell Depression Screening

Image Credits: University of Houston

Keywords: Sepsis; septic shock; nanomedicine; drug delivery; antibacterial therapy; immunomodulation; artificial intelligence; drug repurposing; Alzheimer’s disease; dementia; sickle cell disease; depression screening; pharmaceutical research; University of Houston

Amphotericin B has long been a cornerstone of leishmaniasis treatment; however, its systemic administration can lead to toxicity and adverse health effects. As such, the necessity for delivering this potent antifungal agent directly to infected tissues has become evident. In the study led by Verdan and colleagues, the researchers investigated the potential of utilizing AMF (alternating magnetic fields) to enhance the localization and effectiveness of amphotericin B. Unlike conventional treatment methods that circulate the drug throughout the body, the introduction of nanobiomagnetite allows for targeted therapy, minimizing side effects while maximizing therapeutic action.

Nanobiomagnetite represents a new frontier in drug delivery systems. The nanoparticles interact favorably with the magnetic field generated by AMF, enabling them to be guided towards the leishmania-infected areas. This novel approach not only increases the concentration of the drug at the target site but also reduces the required dosage by allowing for localized delivery. Consequently, the risk of systemic toxicity is significantly diminished. The researchers meticulously discuss tailored physicochemical properties of these nanoparticles to optimize their function in transporting the drug.

Moreover, the study emphasizes the encapsulation capabilities of these nanoparticles, which can effectively shield amphotericin B against degradation and enhance its stability. The nature of the nanobiomagnetite ensures a controlled release of the antifungal agent, achieved by modulating the exposure to the AMF. Such deliberation on timing and dosage is crucial as it can allow for sustained therapeutic levels while mitigating peaks that might lead to adverse effects.

Leishmania amazonensis, a particular species of Leishmania, was chosen for this investigation due to its prevalence and significance in public health. Targeting this pathogen is crucial, especially in endemic regions where the disease imposes a socioeconomic burden. The products of the new delivery system have shown promising results in preliminary tests, demonstrating increased effectiveness in combating this parasitic infection.

One striking aspect of this study is the association of magnetic targeting with biocompatible materials. This attribute adds to the safety profile of the nanobiomagnetite system and provides a dual-functionality that potentially outperforms previous methods. As more pathogens develop resistance to standard treatments, researchers aim for solutions that blend efficacy with minimal health implications, and this innovative system appears to meet this need adequately.

The implications of this research extend beyond just leishmaniasis. The methodologies and technologies developed here could potentially be adapted for other vector-borne diseases, thus broadening the impact on global health. After all, the challenges that arise from drug resistance and the intricacies of treating parasitic infections demand a versatile approach.

Furthermore, potential implications can also be observed in how this technology interacts with the immune system. The delivery of amphotericin B in this novel format may offer the additional benefit of modulating the host’s immune response. By drawing attention to the site of infection, the nanoparticles may not only fight off the pathogen but also improve the overall immune response, rendering it more robust.

Ultimately, the research conducted by Verdan et al. heralds a new chapter in the management of leishmaniasis and possibly other parasitic diseases. The innovation of AMF-responsive nanobiomagnetite for the targeted delivery of a well-established drug exemplifies the importance of interdisciplinary research, combining materials science, pharmacology, and infectious disease expertise, to forge new paths toward effective treatments.

In conclusion, the strides made in this study encapsulate the essence of modern scientific inquiry: addressing fundamental problems with novel solutions. As the world continues to grapple with various infectious diseases, the potential of nanotechnology in drug delivery systems paves the way for a future where targeted therapies can become the norm. The road ahead involves continued research, clinical trials, and a commitment to overcoming the obstacles associated with parasitic infections.

The journey initiated by Verdan et al. brings a beacon of hope not only for combating Leishmania amazonensis but also for enhancing therapeutic strategies across a spectrum of infectious diseases.

Subject of Research: Targeted delivery of amphotericin B using AMF-responsive nanobiomagnetite against Leishmania amazonensis.

Article Title: AMF-responsive nanobiomagnetite for targeted delivery of amphotericin B against Leishmania amazonensis.

Article References:

Verdan, M., Nico, D., Sangenito, L. et al. AMF-responsive nanobiomagnetite for targeted delivery of amphotericin B against Leishmania amazonensis. Sci Rep 15, 39994 (2025). https://doi.org/10.1038/s41598-025-23720-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41598-025-23720-6

Keywords: Leishmania, amphotericin B, nanobiomagnetite, drug delivery, targeted therapy, AMF, infectious diseases.

Traditional medication delivery often suffers from systemic distribution, causing drugs to travel widely throughout the body and interact with unintended tissues, thus triggering undesirable side effects. Psychiatric drugs, for example, might induce dissociation, while painkillers can cause nausea, and chemotherapy typically damages healthy cells along with malignant ones. The novel system developed by the Stanford team encapsulates drugs inside nanoparticles that respond specifically to externally applied ultrasound waves. These waves non-invasively trigger drug release only at targeted sites, offering a level of control and precision unachievable by current methods.

Central to this technology are liposomal nanoparticles—microscopic vesicles with a phospholipid shell—that house the drug in a liquid core. This design draws inspiration from the same kind of nanoparticles used in mRNA COVID-19 vaccines, a nod to the ongoing revolution in nanoparticle production methodologies. The new formulation is not only safer and more stable than previous versions but also easier and more scalable to produce, a crucial factor for potential clinical translation and widespread adoption.

One of the most surprising discoveries is the vital role of a simple kitchen ingredient: sugar. By entrapping a 5% sucrose solution inside the nanoparticle core, the researchers achieved an optimal acoustic contrast necessary for ultrasound detection and activation. This added sucrose increased the density and viscosity of the nanoparticle’s core, creating a subtle but critical difference in acoustic impedance compared to the surrounding tissues. Such contrast ensures that upon ultrasound exposure, the particles resonate and undergo mechanical oscillations, facilitating the controlled release of their drug payload precisely where needed.

The underlying mechanism is believed to involve ultrasound-induced oscillations of the nanoparticle surface against the denser liquid core, which forms transient pores allowing the drug to escape. Despite this insight, the exact biophysical interactions remain under investigation, reflecting the complexity of coupling ultrasound physics and nanomedicine. Importantly, the addition of sucrose helps maintain nanoparticle stability at body temperature and minimizes unwanted premature drug leakage, striking a delicate balance essential for practical therapeutic applications.

Experimental studies on rat models demonstrated the precision and efficacy of this delivery system. Ketamine, a psychoactive drug with dissociative side effects, was encapsulated within these sucrose-loaded nanoparticles and administered systemically. Without ultrasound stimulus, the drug distribution in various organs—including the brain, liver, kidneys, spleen, lungs, heart, and spinal cord—was significantly reduced, indicating minimal off-target exposure. When focused ultrasound was applied to specific brain regions, ketamine release spiked locally, delivering about threefold higher concentrations than in untreated areas, thus enabling targeted neuromodulation.

Remarkably, even a modest 30% increase in local ketamine concentrations had a profound impact on rat behavior. Targeting the medial prefrontal cortex, a brain region regulating emotional states, the team observed measurable reductions in anxiety-like behaviors. Rats receiving the ultrasound-triggered ketamine demonstrated increased exploration of the center of an activity box, a classic indicator of reduced stress. This finding underscores the potential of this technology to isolate therapeutic benefits of psychiatric drugs while mitigating their adverse dissociative effects.

Beyond neuropsychiatric applications, the researchers explored localized pain management by encapsulating ropivacaine, a local anesthetic, within their ultrasound-sensitive nanoparticles. Administering this formulation systemically, they applied brief ultrasound pulses to the sciatic nerve of one leg in rats. The result was a rapid and sustained local anesthetic effect lasting over an hour without affecting the contralateral limb. This approach promises a novel, non-invasive means of inducing regional anesthesia, circumventing the discomfort and complications of direct nerve injections currently employed in clinical practice.

The device’s non-invasive nature offers additional patient benefits, potentially transforming how clinicians manage chronic pain and other localized conditions. Instead of injecting anesthetics or neuromodulatory drugs directly at the site of discomfort, clinicians could administer drugs intravenously and utilize focused ultrasound externally to activate drug release only at the pain site. This strategy not only minimizes procedural pain but also significantly reduces systemic exposure and associated side effects.

Clinical translation of this technology is rapidly approaching. Stanford Medicine’s team, having addressed previous limitations such as the use of exotic and unstable components in early nanoparticle versions, is preparing for initial human trials. Their reliance on liposomal nanoparticles—leveraging existing manufacturing infrastructures developed during the COVID-19 pandemic—and the use of biocompatible ingredients like sucrose significantly increase the likelihood of regulatory approval and commercial scalability. The forthcoming trials aim to assess the system’s efficacy in targeting ketamine to modulate emotional aspects of chronic pain, further bridging neuroscience and pain medicine.

This breakthrough arrives after nearly a decade of research led by Raag Airan, MD, PhD, who emphasizes the transformative potential of combining nanotechnology with acoustically controlled drug delivery. The interdisciplinary work integrates expertise in radiology, materials science, pharmacology, and neurobiology to design a platform that could revolutionize drug administration paradigms. By maximizing therapeutic efficacy while minimizing adverse effects, this technology aligns with the broader precision medicine movement, promising personalized, safe, and highly effective treatments.

The innovation transcends specific drugs tested, offering a universal platform adaptable to various pharmacological agents. Any drug that can be encapsulated within the liposomal nanoparticles and is sensitive to ultrasound-triggered release can, in principle, benefit from this advancement. The system’s modularity and adaptability position it as a generalizable solution for myriad medical conditions across different organ systems.

Funding support from leading institutions including the National Institutes of Health and foundations such as the Ford Foundation underscores the significance and potential impact of this work. As researchers delve deeper into optimizing nanoparticle formulations and exploring ultrasound parameters, the promise of safe, targeted, and non-invasive drug delivery inches closer to becoming a clinical reality that could redefine patient care worldwide.

Subject of Research: Animals

Article Title: Acoustically activatable liposomes as a translational nanotechnology for site-targeted drug delivery and noninvasive neuromodulation

News Publication Date: 18-Aug-2025

Web References:
http://dx.doi.org/10.1038/s41565-025-01990-5

Image Credits: Emily Moskal/Stanford Medicine

Keywords: Nanoparticles, Medications